European Leukemia Trial Registry
Trial: JAKARTA

More Details
Title Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis
Scientific Title A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study of SAR302503 in Patients with Intermediate-2 or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Splenomegaly
Short Title JAKARTA
Trialgroup NN
Type of Trial multicentric, randomized, prospective, double-blind
Disease Myeloproliferative disease(MPD) Myelofibrosis
Age >= 18 years
Status Active
Start of Recruitment 18.07.2012
Leader Reiter, Prof. Dr. med., Andreas
Centre of Trial Medizinische Fakultšt Mannheim der Universitšt Heidelberg
Shortprotocol Shortprotocol
created 14.08.2012 Janina Rosemeier
changed 02.10.2012 Sina Hehn
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org